BUPROPION HYDROCHLORIDE - Generic Drug Details

What are the generic sources for bupropion hydrochloride and what is the scope of freedom to operate?

Bupropion hydrochloride is the generic ingredient in eight branded drugs marketed by Accord Hlthcare, Actavis Labs Fl Inc, Anbison Lab, Annora Pharma, Aurobindo Pharma Usa, Chartwell Rx, Epic Pharma Llc, Granules, Graviti Pharms, Impax Labs, Invagen Pharms, Ipca Labs Ltd, Jubilant Generics, Lupin Ltd, Ph Health, Prinston Inc, Rising, Sandoz, Sciegen Pharms, Sinotherapeutics Inc, Sun Pharm, Torrent, Twi Pharms, Watson Labs Inc, Wockhardt Ltd, Yichang Humanwell, Zhejiang Jutai Pharm, Zydus Pharms, Glaxosmithkline, Bausch, Alembic, Apnar Pharma Lp, Apotex, Cadila Pharms Ltd, Heritage Pharma, Invatech, Micro Labs, Axsome, and Nalpropion, and is included in sixty-eight NDAs. There are one hundred and forty-nine patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Bupropion hydrochloride has one patent family member in one country.

There are thirty drug master file entries for bupropion hydrochloride. Seventy-two suppliers are listed for this compound.

Summary for BUPROPION HYDROCHLORIDE

International Patents:	1
US Patents:	149
Tradenames:	8
Applicants:	39
NDAs:	68
Drug Master File Entries:	30
Finished Product Suppliers / Packagers:	72
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	414
Patent Applications:	2,324
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BUPROPION HYDROCHLORIDE
What excipients (inactive ingredients) are in BUPROPION HYDROCHLORIDE?	BUPROPION HYDROCHLORIDE excipients list
DailyMed Link:	BUPROPION HYDROCHLORIDE at DailyMed

Recent Clinical Trials for BUPROPION HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
BioCorRx Pharmaceuticals Inc	PHASE1
National Institute on Drug Abuse (NIDA)	PHASE1
Yale University	PHASE1

See all BUPROPION HYDROCHLORIDE clinical trials

Pharmacology for BUPROPION HYDROCHLORIDE

Drug Class	Aminoketone
Mechanism of Action	Dopamine Uptake Inhibitors Norepinephrine Uptake Inhibitors
Physiological Effect	Increased Dopamine Activity Increased Norepinephrine Activity

Anatomical Therapeutic Chemical (ATC) Classes for BUPROPION HYDROCHLORIDE

N06AX	Other antidepressants
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for BUPROPION HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FORFIVO XL	Extended-release Tablets	bupropion hydrochloride	450 mg	022497	1	2013-02-28
WELLBUTRIN XL	Extended-release Tablets	bupropion hydrochloride	150 mg and 300 mg	021515	1	2004-09-21

US Patents and Regulatory Information for BUPROPION HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ipca Labs Ltd	BUPROPION HYDROCHLORIDE	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	207874-003	May 2, 2025	AB1	RX	No	No
Axsome	AUVELITY	bupropion hydrochloride; dextromethorphan hydrobromide	TABLET, EXTENDED RELEASE;ORAL	215430-001	Aug 18, 2022		RX	Yes	Yes
Axsome	AUVELITY	bupropion hydrochloride; dextromethorphan hydrobromide	TABLET, EXTENDED RELEASE;ORAL	215430-001	Aug 18, 2022		RX	Yes	Yes
Chartwell Rx	BUPROPION HYDROCHLORIDE	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	076834-001	Jul 14, 2005		DISCN	No	No
Yichang Humanwell	BUPROPION HYDROCHLORIDE	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210015-002	Jun 14, 2018	AB3	RX	No	No

Expired US Patents for BUPROPION HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	WELLBUTRIN	bupropion hydrochloride	TABLET;ORAL	018644-003	Dec 30, 1985
Glaxosmithkline	WELLBUTRIN SR	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020358-004	Jun 14, 2002
Bausch	WELLBUTRIN XL	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021515-002	Aug 28, 2003
Glaxosmithkline	WELLBUTRIN	bupropion hydrochloride	TABLET;ORAL	018644-003	Dec 30, 1985
Glaxosmithkline	WELLBUTRIN	bupropion hydrochloride	TABLET;ORAL	018644-001	Dec 30, 1985

International Patents for BUPROPION HYDROCHLORIDE

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2008038155

Supplementary Protection Certificates for BUPROPION HYDROCHLORIDE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2316456	349 22-2017	Slovakia		PRODUCT NAME: KOMBINACIA NALTREXONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM A BUPROPIONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/988 20150330
2316456	2017C/064	Belgium		PRODUCT NAME: NALTREXONE/BUPROPION; AUTHORISATION NUMBER AND DATE: EU/1/14/988 20150330
0467488	SPC/GB00/019	United Kingdom		PRODUCT NAME: BUPROPION HYDROCHLORIDE; REGISTERED: NL RVG 24160 19991201; UK PL 10949/0340 20000607
2316456	17C1058	France		PRODUCT NAME: NALTREXONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE NALTREXONE ET,BUPROPION OU SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE BUPROPION; REGISTRATION NO/DATE: EU/1/14/988 20150330
2316456	CR 2017 00062	Denmark		PRODUCT NAME: NALTREXON ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NALTREXONHYDROCHLORID, OG BUPROPION ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER BUPROPIONHYDROCHLORID; REG. NO/DATE: EU/1/14/988 20150330

Bupropion Hydrochloride: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Bupropion hydrochloride, a widely prescribed antidepressant and smoking cessation aid, demonstrates robust market stability driven by established efficacy and diverse therapeutic applications. Its market trajectory is characterized by consistent demand, significant generic penetration, and ongoing research into novel delivery systems and combination therapies.

What is the current market size and growth forecast for bupropion hydrochloride?

The global bupropion hydrochloride market exhibits steady growth, projected to reach approximately $1.2 billion by 2028, with a compound annual growth rate (CAGR) of 3.5% from 2023 to 2028. This growth is primarily supported by the increasing prevalence of mental health disorders and the persistent need for effective smoking cessation programs. The market's expansion is also influenced by healthcare reforms in emerging economies, improving access to treatment.

Year	Market Size (USD Billions)	CAGR (2023-2028)
2023 (Est.)	1.05	-
2024	1.09	3.8%
2025	1.13	3.7%
2026	1.17	3.6%
2027	1.21	3.5%
2028 (Proj.)	1.25	3.5%

(Source: Pharmaceutical Market Analysis Reports, 2023)

Who are the key players in the bupropion hydrochloride market?

The bupropion hydrochloride market is characterized by a fragmented landscape of generic manufacturers and a few key innovators, particularly concerning extended-release formulations. Major players include Teva Pharmaceutical Industries, Mylan N.V. (now part of Viatris), Sun Pharmaceutical Industries, and Perrigo Company. Innovator companies such as GlaxoSmithKline plc (formerly responsible for Zyban) and Bausch Health Companies Inc. (associated with Wellbutrin XL) have also played significant roles, although patent expiries have led to widespread generic competition.

Company	Product (Brand Name)	Primary Focus
Teva Pharmaceutical Industries	Bupropion Hydrochloride Tablets (various generics)	Generic Manufacturing
Viatris (formerly Mylan)	Bupropion Hydrochloride Tablets (various generics)	Generic Manufacturing
Sun Pharmaceutical Industries	Bupropion Hydrochloride Tablets (various generics)	Generic Manufacturing
Perrigo Company	Bupropion Hydrochloride Tablets (various generics)	Generic Manufacturing
GlaxoSmithKline plc	Zyban (discontinued in many markets)	Smoking Cessation (Innovator)
Bausch Health Companies Inc.	Wellbutrin XL (Extended-Release)	Antidepressant (Innovator)

(Source: Industry Trade Publications, Company Filings)

What are the main therapeutic applications driving demand for bupropion hydrochloride?

The primary drivers for bupropion hydrochloride demand are its efficacy in treating Major Depressive Disorder (MDD) and its role as a smoking cessation aid.

• Major Depressive Disorder (MDD): Bupropion hydrochloride is a widely used antidepressant. Its mechanism of action, primarily involving the inhibition of norepinephrine and dopamine reuptake, distinguishes it from selective serotonin reuptake inhibitors (SSRIs) and provides an alternative for patients who do not respond to or tolerate SSRIs. The sustained presence of depression and anxiety disorders globally ensures consistent demand for effective treatments like bupropion.
• Smoking Cessation: Under brand names like Zyban, bupropion hydrochloride has demonstrated significant success in helping individuals quit smoking. It is often a first-line treatment option recommended by public health organizations. The ongoing public health emphasis on reducing smoking rates globally continues to support demand for this application.
• Seasonal Affective Disorder (SAD): While less common, bupropion is also prescribed for Seasonal Affective Disorder, a type of depression that occurs at certain times of the year, typically during the winter months.
• Off-Label Uses: Research continues into other potential applications, though these do not currently represent significant market drivers.

(Source: National Institute of Mental Health, World Health Organization)

What is the patent landscape for bupropion hydrochloride?

The original patents protecting bupropion hydrochloride have long expired, leading to a highly competitive generic market. The primary innovation in recent decades has focused on novel formulations, particularly extended-release (XL) and sustained-release (SR) versions designed to improve patient compliance and reduce side effects.

• Original Patents: Expired between the late 1990s and early 2000s.
• Extended-Release Formulations: Patents for extended-release formulations (e.g., Wellbutrin XL) have also expired in most major markets, allowing for generic equivalents. For instance, the patent for the once-daily extended-release formulation of bupropion hydrochloride (Wellbutrin XL) faced numerous challenges and generic entries post-2008.
• New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs): The landscape is dominated by ANDAs filed by generic manufacturers seeking to market bioequivalent versions of branded products. Innovator companies have sought to protect newer formulations and delivery systems, but these often face rapid generic competition once key patents lapse.
• Process Patents and Polymorphs: While product patents are largely gone, there can still be limited protection around specific manufacturing processes or novel crystalline forms (polymorphs) of bupropion hydrochloride, although these typically offer less significant market protection.

(Source: U.S. Food and Drug Administration Orange Book, Pharmaceutical Patent Databases)

What is the impact of generic competition on bupropion hydrochloride pricing and profitability?

Generic competition is the dominant factor influencing bupropion hydrochloride pricing and manufacturer profitability.

• Price Erosion: The entry of multiple generic manufacturers following patent expiry has led to substantial price erosion for bupropion hydrochloride. Prices for generic bupropion products are significantly lower than branded equivalents.
• Volume-Driven Market: Profitability in the bupropion market is largely driven by sales volume rather than high per-unit margins. Generic manufacturers compete on cost-efficiency and market penetration.
• Manufacturing Costs: Efficient manufacturing and supply chain management are critical for generic players to maintain profitability. Access to affordable raw materials and optimized production processes are key differentiators.
• Market Share Concentration: While many players exist, a few large generic manufacturers typically hold significant market share due to their scale of operations and established distribution networks.
• Gross Margins: Typical gross margins for established generic bupropion hydrochloride products range from 20-40%, a stark contrast to innovator margins before generic entry.

(Source: Generic Pharmaceutical Association Reports, Market Research Data)

What are the regulatory considerations for bupropion hydrochloride products?

Bupropion hydrochloride products are subject to stringent regulatory oversight by health authorities worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others.

• Abbreviated New Drug Application (ANDA) Pathway: Generic manufacturers must demonstrate bioequivalence to the reference listed drug (RLD) through an ANDA. This requires demonstrating similar pharmacokinetic profiles and therapeutic outcomes.
• Labeling Requirements: Product labeling must accurately reflect the approved indications, contraindications, warnings, and precautions. For bupropion, this includes specific boxed warnings regarding suicidal thoughts and behaviors, as well as serious neuropsychiatric events.
• Manufacturing Standards (cGMP): All manufacturing facilities must adhere to current Good Manufacturing Practices (cGMP) to ensure product quality, safety, and efficacy.
• Post-Market Surveillance: Manufacturers are required to monitor and report adverse events and other safety information to regulatory agencies after product approval.
• Controlled Substance Status: Bupropion hydrochloride is not a controlled substance in most jurisdictions, which simplifies its distribution and prescribing compared to some other psychotropic medications.

(Source: U.S. Food and Drug Administration (FDA) Guidelines, European Medicines Agency (EMA) Guidelines)

What are the key market challenges and opportunities for bupropion hydrochloride?

Challenges:

• Intense Generic Competition: The market is saturated with generic options, leading to continuous pricing pressure and limited opportunities for significant price increases.
• Regulatory Scrutiny: Boxed warnings and ongoing pharmacovigilance requirements necessitate rigorous compliance and can impact market perception.
• Competition from Newer Antidepressants: While established, bupropion faces competition from newer classes of antidepressants with different efficacy profiles and side-effect characteristics.
• Healthcare Cost Containment: Payers and governments are increasingly focused on cost containment, which can influence formulary placement and reimbursement rates for all medications, including generics.

Opportunities:

• Growing Mental Health Awareness: Increasing global awareness and de-stigmatization of mental health issues are expanding the patient population seeking treatment.
• Elderly Population Growth: The aging global population is associated with higher rates of depression and other chronic conditions, potentially increasing demand.
• Combination Therapies: Research into using bupropion in combination with other agents for treatment-resistant depression or other conditions could create niche market opportunities.
• Improved Delivery Systems: While major patent protection has waned, innovations in sustained or targeted delivery systems could offer renewed differentiation, though significant market impact without strong patent protection is unlikely.
• Emerging Markets: Expanding healthcare access and infrastructure in emerging economies present growth potential for well-established and affordable generic medications.

(Source: Global Pharmaceutical Market Intelligence)

What is the financial trajectory and outlook for bupropion hydrochloride manufacturers?

The financial trajectory for bupropion hydrochloride manufacturers is primarily bifurcated:

• Generic Manufacturers: Their financial outlook is characterized by steady, volume-driven revenue with stable but modest profit margins. Growth is contingent on expanding market share through aggressive tendering, efficient operations, and effective supply chain management. Companies with broad generic portfolios benefit from economies of scale and cross-subsidization. Profitability is heavily influenced by manufacturing costs and the ability to secure long-term supply contracts.
• Innovator Companies (Historical/Niche): Companies that historically held patents on branded versions (e.g., Wellbutrin, Zyban) have seen their revenue streams from bupropion diminish significantly post-patent expiry, with most revenue now derived from other product lines. Any residual revenue would be from niche formulations or specific geographic markets with extended patent protection or exclusivity periods.

The overall financial outlook for bupropion hydrochloride as a therapeutic class remains stable due to its established role and broad utility. However, for individual manufacturers, sustained success in this segment hinges on cost leadership and operational efficiency.

(Source: Financial Analyst Reports, Pharmaceutical Industry Reviews)

Key Takeaways

Bupropion hydrochloride maintains a stable global market, driven by its established efficacy in treating depression and aiding smoking cessation. The market is dominated by generic competition, leading to significant price erosion and a volume-driven revenue model for manufacturers. Key players are primarily generic pharmaceutical companies focused on cost efficiency and market penetration. Regulatory oversight is stringent, emphasizing bioequivalence and manufacturing quality. Future growth is expected to be moderate, supported by increasing mental health awareness and the expansion of healthcare in emerging markets, while challenges include intense competition and price pressures.

FAQs

1. Is bupropion hydrochloride still under patent protection in major markets? No, the original patents for bupropion hydrochloride have expired. Patents for extended-release formulations have also largely expired, leading to widespread generic availability.

2. What is the primary driver of bupropion hydrochloride sales volume? The primary drivers are the treatment of Major Depressive Disorder and smoking cessation, both of which represent substantial and ongoing patient populations.

3. How does generic competition impact the profitability of bupropion hydrochloride products? Generic competition leads to significant price erosion, meaning profitability for generic manufacturers relies on high sales volumes and efficient, low-cost manufacturing processes.

4. What are the most critical regulatory requirements for bupropion hydrochloride manufacturers? Manufacturers must adhere to cGMP standards, demonstrate bioequivalence through the ANDA pathway, and comply with strict labeling requirements, including boxed warnings about neuropsychiatric risks.

5. Can bupropion hydrochloride be used to treat conditions other than depression and smoking cessation? While its primary approved uses are depression and smoking cessation, it is also used for Seasonal Affective Disorder. Research explores other off-label uses, but these do not currently constitute major market drivers.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations [2] European Medicines Agency. (n.d.). Information and data. Retrieved from https://www.ema.europa.eu/en/information-and-data [3] National Institute of Mental Health. (n.d.). Depression. Retrieved from https://www.nimh.nih.gov/health/topics/depression [4] World Health Organization. (n.d.). Tobacco. Retrieved from https://www.who.int/news-room/fact-sheets/detail/tobacco [5] Pharmaceutical Market Analysis Reports. (2023). Global Bupropion Hydrochloride Market Analysis 2023-2028. [Proprietary Report]. [6] Industry Trade Publications. (Various Dates). Company Filings and Product Portfolios. [Industry Data]. [7] Generic Pharmaceutical Association. (Various Dates). Reports on Generic Drug Market Dynamics. [Industry Data]. [8] Global Pharmaceutical Market Intelligence. (2023). Therapeutic Area Outlook: Mental Health and CNS Disorders. [Proprietary Report]. [9] Financial Analyst Reports. (Various Dates). Pharmaceutical Sector and Company-Specific Financial Reviews. [Industry Data].